Evofem Biosciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 8.56 million compared to USD 125.98 million a year ago. Basic loss per share from continuing operations was USD 5.43.
For the six months, net loss was USD 10.91 million compared to USD 157.87 million a year ago. Basic loss per share from continuing operations was USD 6.6.